Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VVUS

VIVUS (VVUS) Stock Price, News & Analysis

VIVUS logo

About VIVUS Stock (NASDAQ:VVUS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.26
$0.47
52-Week Range
N/A
Volume
2.03 million shs
Average Volume
1.44 million shs
Market Capitalization
$7.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive VVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

VVUS Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS Shares Significant Regulatory Update on QSYMIA®
VIVUS Announces Label Update for QSYMIA®
See More Headlines

VVUS Stock Analysis - Frequently Asked Questions

VIVUS, Inc. (NASDAQ:VVUS) announced its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter.

VIVUS shares reverse split on the morning of Tuesday, September 11th 2018.The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Novavax (NVAX), CymaBay Therapeutics (CBAY) and Amarin (AMRN).

Company Calendar

Last Earnings
5/06/2020
Today
7/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VVUS
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.50 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$69.76 million
Price / Cash Flow
N/A
Book Value
($6.50) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$7.33 million
Optionable
Optionable
Beta
-0.84
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:VVUS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners